174 related articles for article (PubMed ID: 8492955)
1. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial myopathy caused by long-term zidovudine therapy.
Dalakas MC; Illa I; Pezeshkpour GH; Laukaitis JP; Cohen B; Griffin JL
N Engl J Med; 1990 Apr; 322(16):1098-105. PubMed ID: 2320079
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy.
Morgello S; Wolfe D; Godfrey E; Feinstein R; Tagliati M; Simpson DM
Acta Neuropathol; 1995; 90(4):366-74. PubMed ID: 8546027
[TBL] [Abstract][Full Text] [Related]
4. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.
Grau JM; Masanés F; Pedrol E; Casademont J; Fernández-Solá J; Urbano-Márquez A
Ann Neurol; 1993 Aug; 34(2):206-11. PubMed ID: 8338345
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in AZT myopathy.
Chalmers AC; Greco CM; Miller RG
Neurology; 1991 Aug; 41(8):1181-4. PubMed ID: 1714057
[TBL] [Abstract][Full Text] [Related]
8. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
Schröder JM; Bertram M; Schnabel R; Pfaff U
Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
[TBL] [Abstract][Full Text] [Related]
9. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy.
Rosenfeldt FL; Mijch A; McCrystal G; Sweeney C; Pepe S; Nicholls M; Dennett X
Int J STD AIDS; 2005 Dec; 16(12):827-9. PubMed ID: 16336769
[TBL] [Abstract][Full Text] [Related]
10. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction.
Casademont J; Barrientos A; Grau JM; Pedrol E; Estivill X; Urbano-Márquez A; Nunes V
Brain; 1996 Aug; 119 ( Pt 4)():1357-64. PubMed ID: 8813297
[TBL] [Abstract][Full Text] [Related]
11. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
[TBL] [Abstract][Full Text] [Related]
13. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team.
Simpson DM; Katzenstein DA; Hughes MD; Hammer SM; Williamson DL; Jiang Q; Pi JT
AIDS; 1998 Dec; 12(18):2425-32. PubMed ID: 9875580
[TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
[TBL] [Abstract][Full Text] [Related]
15. Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment.
Panegyres PK; Papadimitriou JM; Hollingsworth PN; Armstrong JA; Kakulas BA
J Neurol Neurosurg Psychiatry; 1990 Aug; 53(8):649-55. PubMed ID: 2170584
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
Pinching AJ; Helbert M; Peddle B; Robinson D; Janes K; Gor D; Jeffries DJ; Stoneham C; Mitchell D; Kocsis AE
J Infect; 1989 Jan; 18 Suppl 1():33-40. PubMed ID: 2521663
[TBL] [Abstract][Full Text] [Related]
17. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection.
Baldeweg T; Catalan J; Lovett E; Gruzelier J; Riccio M; Hawkins D
AIDS; 1995 Jun; 9(6):589-96. PubMed ID: 7662198
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
Pezeshkpour G; Illa I; Dalakas MC
Hum Pathol; 1991 Dec; 22(12):1281-8. PubMed ID: 1748434
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.
Schmitt FA; Bigley JW; McKinnis R; Logue PE; Evans RW; Drucker JL
N Engl J Med; 1988 Dec; 319(24):1573-8. PubMed ID: 3059187
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle involvement in HIV-infected patients.
Gherardi RK
Neuropathol Appl Neurobiol; 1994 Jun; 20(3):232-7. PubMed ID: 7936072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
